Treatment for solid tumors with HER2 mutations using BAY2927088 tablets

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of BAY2927088 tablets in patients with advanced solid tumors that have mutations in the HER2 gene. The study focuses on various types of cancers, including colorectal, biliary tract, bladder, and cervical cancers, while excluding non-small cell lung cancer. Participants must have a documented HER2 mutation and measurable lesions to qualify for the trial. The goal is to understand how well this treatment can block the abnormal HER2 protein associated with tumor growth.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; breast cancer; other solid tumor cancer, excluding NSCLC)
* Participant must be ≥18 years of age or over the legal age of consent
* Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments
* Documented activating HER2 mutation
* At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria

Exclusion Criteria:

* Primary diagnosis of non-small cell lung cancer (NSCLC)
* Prior treatment with a HER2 tyrosine kinase inhibitor (TKI)
* Active brain metastases
* Uncontrolled, severe, intercurrent illness

Where it's running

• City of Hope - Duarte Cancer Center
  Duarte, California, United States Recruiting
• Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus
  Fort Myers, Florida, United States Recruiting
• Dana-Farber Cancer Institute - Oncology Department
  Boston, Massachusetts, United States Recruiting
• Cleveland Clinic - Oncology Department
  Cleveland, Ohio, United States Recruiting
• SCRI Oncology Partners
  Nashville, Tennessee, United States Recruiting
• The University of Texas MD Anderson Cancer Center - Texas Medical Center
  Houston, Texas, United States Recruiting

+4 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Bayer Clinical Trials Contact
• Email: clinical-trials-contact@bayer.com
• Phone: 0018888422937

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Sevabertinib in HER2-mutant Advanced NSCLC: Real-world Outcomes

  This study looks at how Sevabertinib works in real-world adults with HER2-mutant advanced NSCLC who have had prior treatment, to see its effectiveness, safety, and impact on quality of life.

  Recruiting Ruijin Hospital · Qionghai, Hainan · NCT07880353

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• MK-2010 alone or with other treatments for advanced solid tumors

  This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.

  Recruiting at 7 sites Phase 2 Merck Sharp & Dohme LLC · Belleville, New Jersey and 6 other locations · NCT07793942

• Whole-Body Infrared Heating for Advanced Solid Tumors

  This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.

  Recruiting Zhejiang Hospital · Hangzhou, Zhejiang · NCT07793214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.